Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06354829
Active, not recruiting Observational

Medical Images Collection Research

NCT06354829 · tracked via the Priya Life Science Italy tracker
Sponsor
Mario Negri Institute for Pharmacological Research
Phase
Observational
Started
2025-01-07
Last updated
2025-09-04

Condition(s) studied

Kidney DiseasesBrain Diseases

Investigational drug(s) / intervention(s)

Medical imaging procedures

Medical imaging procedures: The following medical imaging procedure will b applied: Magnetic resonance images (MRI), computerized tomography images (CT), and ultrasound images (US).

Study summary

This is a not-for-profit project for the collection, archiving and reuse of magnetic resonance imaging, computed tomography and ultrasound images, and related demographic and clinical data, for research purposes only.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy subjects: Adults ≥ 18 years; Subjects with no previous history of kidney or cerebral disease * Patients: Adults ≥ 18 years; Subjects with renal or cerebral disease Exclusion Criteria: * N/A

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinical Research Center for Rare Disease Aldo e Cele Daccò Ranica BG

More Mario Negri Institute for Pharmacological Research trials in Italy

RESOLving INflammation Through Diet for Health (RESOLVIN) Recruiting
Severe Acquired Brain Injuries: Prognostic Factors and Quality of Care Recruiting
Health-care Quality in Semi-intensive Care Units Recruiting
Development of a Natural Language Processing Tool to Enable Clinical Research in Emergency Medicine Recruiting
NASCITA Italian Birth Cohort Study Active, not recruiting

Other trials for the same condition

Long Term Extension Study in Patients With Primary Hyperoxaluria Active, not recruiting
TreaT-Assay: the New Frontier for the Diagnosis of Acute Rejection in Kidney Transplantation Recruiting
Hyperthyroidism as a Potential Predictive of Worse Outcome of Renal Graft Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06354829 on ClinicalTrials.gov ↗ ← All trials in Italy